Gitika Panicker's research while affiliated with Centers for Disease Control and Prevention and other places

Publications (49)

Article
Full-text available
Human papillomavirus (HPV) causes cervical cancer among women and is associated with other anogenital cancers in men and women. Prophylactic particulate vaccines that are affordable, self-administered and efficacious could improve uptake of HPV vaccines world-wide. The goal of this research is to develop a microparticulate HPV16 vaccine for transde...
Article
Well-characterized HPV serology assays are required to evaluate performance of biosimilar candidate vaccines, reduced dosing schedules and novel administration methods. We report characterization of an expanded assay, M9ELISA, that detects antibodies to HPV virus-like particles (VLP) of nine types using direct IgG ELISA on the Meso Scale Discovery...
Article
Full-text available
High-risk human papillomavirus (HPV) is prevalent and known to cause 5% of all cancers worldwide. The rare, cancer prone Fanconi anemia (FA) population is characterized by a predisposition to both head and neck squamous cell carcinomas and gynecological cancers, but the role of HPV in these cancers remains unclear. Prompted by a patient-family advo...
Article
Full-text available
Background Immune dysfunction related to HIV infection is associated with an inability to clear HPV infection and may compromise the immunogenicity of quadrivalent HPV vaccine Gardasil® (4v HPV). Methods Between 2005 and 2017, males and females 7 to 20 years old age, were offered 3-dose 4v HPV vaccine. Plasma IgG titers to HPV 6 (H6), 11 (H11), 16...
Article
Objective In the United States, HPV vaccination is routinely recommended at age 11 or 12 years; the series can be started at age 9. We conducted a cohort study to assess long-term immunogenicity of quadrivalent HPV vaccine (4vHPV) in an American Indian/Alaska Native (AI/AN) Indigenous population. Methods During 2011–2014, we enrolled AI/AN girls a...
Article
Full-text available
Introduction Whether existing serological assays are sufficiently robust to measure the lower antibody levels expected following single-dose HPV vaccination is unknown. Methods We evaluated seven assays measuring HPV-16/18 immunological responses overall and by number of doses in 530 serum samples from participants receiving varying doses of Cerva...
Article
Full-text available
Human papillomavirus virus (HPV) vaccines aim to provide durable protection and are ideal to study the association of cellular with humoral responses. We assessed the duration and characteristics of immune responses provided by the quadrivalent HPV (4vHPV) vaccine in healthy female adults with or without prior exposure with type 16 and 18 HPV. In a...
Article
Full-text available
Background: Vaccine-induced human papillomavirus (HPV) antibodies originating from cervicovaginal secretions were recently shown to be detectable in first-void (FV) urine. This presents a novel opportunity for non-invasive sampling to monitor HPV antibody status in women participating in large epidemiological studies and HPV vaccine trials. With a...
Article
Objective: There is a high prevalence of human papillomavirus (HPV) infection in Puerto Rico, but little is known about the prevalence of Chlamydia trachomatis (CT) infection in healthy Puerto Rican women. Thus we aimed to evaluate the seroprevalence and association and the association between HPV and CT. Methods: This was a secondary data analy...
Article
Full-text available
The quadrivalent HPV vaccine (4vHPV) was originally recommended as a three-dose series (0/2/6 months), though delays in completing the series frequently occur. We previously found delayed dosing in girls resulted in similar or higher antibody titers compared to on-time dosing. Archived sera from 262 healthy females aged 9–18 recruited from pediatri...
Article
Background: Human papillomavirus (HPV) prevalence is high among men who have sex with men (MSM), yet little is known about HPV among transgender women (TGW). We assessed HPV prevalence and knowledge among TGW compared with MSM. Methods: We enrolled TGW and MSM aged 18 to 26 years from clinics in Chicago and Los Angeles during 2012 to 2014. Parti...
Article
The main objective of this post hoc analysis is to compare the magnitude of the immune response to HPV31/33/45/52 and 58 after a dose of 9vHPV vaccine given to naïve (previously unvaccinated) subjects and subjects previously vaccinated with a dose of 2vHPV or 4vHPV vaccine. Results from two clinical trials conducted in the same region, in comparabl...
Article
The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6- month or a 3-8 year interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA methodology were compared. In...
Article
Background: Differences in human papillomavirus (HPV) seroprevalence by sex have been observed, likely due to differences in the anatomic site of HPV exposure. Seroconversion may be more likely after exposure at non-keratinized (mucosal) compared to keratinized epithelium. We compared seroprevalence among self-identified gay/bisexual men who have...
Article
Background: Limited data is available on the use of different HPV vaccines in the same subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent (9vHPV) and one dose of bivalent vaccine (2vHPV) administered in different order versus two doses of 9vHPV vaccine. Methods: 371 girls and boys age...
Article
Full-text available
The objective of this study was to assess the persistence of antibodies after a single dose of quadrivalent HPV vaccine (4vHPV) and the effect of a dose of nonavalent HPV vaccine (9vHPV) given 3–8 years later. Such data might be of interest in the decision-making process regarding the 2-dose course completion in non-compliant vaccinees in jurisdict...
Article
Full-text available
Background: To understand risk factors for HPV exposure in Puerto Rican women, we evaluated HPV 6, 11, 16, and 18 serology in women aged living in the San Juan metropolitan area. Methods: As part of a cross-sectional study, a population-based sample of 524 HPV unvaccinated Hispanic women ages 16-64 years completed face-to-face and computer assis...
Article
Full-text available
Objective: It is unknown if human papillomavirus (HPV) serum antibody responses vary by anatomic site of infection. We aimed to assess the seroprevalence for HPV 6, 11, 16 and 18 in association with HPV DNA detection in different anatomic sites among women. Methods: This cross sectional population-based study analyzed data from 524 women aged 16...
Article
Background: The originally recommended dosing schedule, 0, 2, 6 months, for the 3-dose quadrivalent human papillomavirus vaccine (4vHPV) was often not followed, resulting in longer than recommended intervals between doses and interest in the effect of prolonged intervals. Recent two-dose recommendations require investigations into the effect of de...
Article
Fanconi anemia (FA) is a rare genetic disorder associated with predisposition to head and neck and gynecological squamous cell cancers. In the general population, these cancers are commonly linked to human papillomavirus (HPV) infection. Antibodies to natural HPV infection and HPV vaccination were evaluated in 63 individuals with FA while consideri...
Article
Full-text available
Background: The most recent (2012) worldwide estimates from International Agency for Research on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are attributed to cervical cancer worldwide. The disease is preventable with HPV vaccination and with early detection and treatment of pre-invasive cervical intraepithelial...
Article
Limited data exists regarding antibody avidity for human papillomavirus (HPV). We describe development of a multiplex electrochemiluminescent avidity ELISA for four HPV types (HPV 6, 11, 16, 18) by adding a dissociating step to our established multiplex HPV VLP ELISA. Initial experiments exploring ammonium thiocyanate, sodium thiocyanate and guanid...
Article
Full-text available
Background: Gay, bisexual, and other men who have sex with men (MSM) are at high risk for HPV; vaccination is recommended for U.S. males, including MSM through age 26. We assessed evidence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact. Methods: During 2012-14, MSM age 18-26 at selected clinics completed a comp...
Article
Background: A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) types (31/33/45/52/58). Measuring seropositivity before vaccine introduction provides baseline data on exposure to types targeted by vaccines. Methods: We determined s...
Article
Full-text available
Background Fanconi Anemia (FA) is a rare genetic disorder resulting in a loss of function of the FA-related DNA repair pathway. Individuals with FA are predisposed to some cancers including oropharyngeal and gynecological cancers with known associations with human papillomavirus (HPV) in the general population. Since individuals with FA respond poo...
Article
Quadrivalent human papillomavirus vaccine (HPV4) is recommended as a 3-dose series administered at 0, 1-2, and 6 months. However, this dosing schedule is often not followed leading to longer dosing intervals. We conducted a prospective study to assess antibody titers to HPV4 when dose 2 and/or dose 3 were administered on schedule or delayed. Health...
Article
Full-text available
Objective: Since 2006, human papillomavirus (HPV) vaccination has been routinely recommended for adolescent females in the USA. The quadrivalent vaccine induces long-term seropositivity to HPV 6/11/16, which may be useful as a marker for HPV vaccine coverage. Methods: We evaluated vaccine type seropositivity (i.e., seropositivity to HPV 6/11/16 wit...
Article
Reliable antibody based-assays are needed to evaluate the immunogenicity of current vaccines, impact of altered dosing schemes or of new vaccine formulations. An ideal assay platform would allow multiplex type-specific detection with minimal sample requirement.We used the Meso Scale Discovery (MSD) electrochemiluminescence based detection platform...
Article
A vaccine is available to prevent human papillomavirus (HPV) 6, 11, 16 and 18; in the prevaccine era, seropositivity to vaccine types is a measure of natural exposure. We describe HPV seropositivity in the USA among 14-59-year-olds using the 2003-2006 National Health and Nutrition Examination Surveys. Seropositivity to HPV 6, 11, 16 and 18 was 17.5...
Article
Full-text available
This study aimed to estimate the prevalence and correlates of seropositivity to human papillomavirus (HPV)-16 in a subsample of adults who participated in the parent study Epidemiology of Hepatitis C in the adult population of Puerto Rico (PR). The parent study was a population-based household survey aimed to estimate the seroprevalence of hepatiti...
Article
There are limited data on the proportion who have been exposed to vaccine-type human papillomavirus (HPV) among women attending sexually transmitted disease (STD) clinics; this information could inform the potential benefits of HPV vaccination for women attending this venue. Human papillomavirus surveillance was conducted in STD clinics in Baltimor...
Article
Solid organ transplant recipients are at risk of morbidity from human papillomavirus (HPV)-related diseases. Quadrivalent HPV vaccine is recommended for posttransplant patients but there are no data on vaccine immunogenicity. We determined the immunogenicity of HPV vaccine in a cohort of young adult transplant patients. Patients were immunized with...
Article
Full-text available
SELDI-TOF mass spectrometer's compact size and automated, high throughput design have been attractive to clinical researchers, and the platform has seen steady-use in biomarker studies. Despite new algorithms and preprocessing pipelines that have been developed to address reproducibility issues, visual inspection of the results of SELDI spectra pre...
Conference Paper
Background: Two HPV vaccines are available and recommended for use in adolescent girls aged 11 or 12 years of age. Although catch-up vaccination of 13-26 year olds is also recommended, the benefits of vaccine in this age group, especially those who have had sexual experience, are likely less. There are limited data from STD clinics on the proportio...
Article
Full-text available
Suitably controlled serosurveillance surveys are essential for evaluating human papillomavirus (HPV) immunization programs. A panel of plasma samples from 18-year-old females was assembled, the majority of the samples being from recipients of the bivalent HPV vaccine. Antibody specificities were evaluated by three independent laboratories, and 3 po...
Article
of a paper presented at Microscopy and Microanalysis 2011 in Nashville, Tennessee, USA, August 7–August 11, 2011.
Article
Full-text available
Introduction Cervical cancer is among the most common cancers in women worldwide. Discovery of biomarkers for the early detection of cervical cancer would improve current screening practices and reduce the burden of disease. Objective In this study, we report characterization of the human cervical mucous proteome as the first step towards protein...
Article
Cervical mucous, produced in the region where cervical neoplasia occurs, is thought to be a good choice for discovery of biomarkers to improve cervical cancer screening. In this study, SELDI-TOF MS analysis was used to evaluate parameters for protein profiling of mucous. Proteins were extracted from mucous collected with Weck-Cel sponges. Several p...
Article
Full-text available
Cytokines have progressively come to serve as indicators for the presence or severity of a disease. But accurate measurement of cytokine levels can be deterred by lack of proper handling and storage of the samples. In this study, we attempted to measure the effect of snap-freezing and refrigeration at the time of collection on cervical mucous. Lumi...

Citations

... The mean age of women was 44 (range 27-72), and the age group most affected was that of the 40-50-year old. Histological examination revealed the presence of HPV16 in women with different grades of cervical dysplasia [8]. It is appropriate to discuss immunization for high-risk groups. ...
... Epidemiological studies have shown that persons with FA are at substantially higher risk of having oral HPV (versus non-FA controls) [202]. This suggests that apart from its role in the repair of DNA ICLs, the FA pathway suppresses HPV infection or persistence. ...
... This assay has previously been evaluated for monitoring antibody responses following single-dose HPV vaccination. 13 Antibody seropositivity was defined as concentrations equal to or greater than the assay threshold (1·309 IU/mL for HPV 16 and 1·109 IU/mL for HPV 18). The HPV 16 and HPV 18 specific antibody avidity index in the ELISA was determined by the ratio of antibody concentrations in serum samples treated or not treated with Guanidine-HCl (GuHCl). ...
... However, they are typically not considered direct immunotherapeutic compounds. Furthermore, calcineurin inhibitor cyclosporine A and protein kinase C inhibitor sotrastaurin, together with vaccines against hepatitis B and human papillomavirus (viruses known to cause malignancies) were not included in immunological targets presented in Table 1, even though strictly fulfilling our definition of immunotherapeutic agents (119)(120)(121)(122). The first two were not included in the original search due to not (yet) being recognized as relevant targets in in immuno-oncology, meaning the possible use in immuno-oncology was not confirmed by literature, although that might change in the future. ...
... For example microbiota studies demonstrated that high proportion of Atopobium, Prevotella, Gardnerella, and in some studies, Megasphoera and L. gasseri species in women along with CSTs III (microbial dominance of L. iners) or with a subtype of CST-IV, probably are HPVpositive and have higher rates in HPV-positive woman, and also have slower enhancement and viral clearance [121,131]. Also sometimes HPV facilitates other infections, like Chlamydia trachomatis [132]. Moreover there is evidence indicating that microbiota can prevent HPV infection by producing d-lactic acid, producing hydrogen peroxide, and blocking HPV adherence to vaginal epithelial cells by forming a microbial physical barrier [96,114]. ...
... The second study compared the measurement of HPV antibodies in FV urine using a multiplex L1/L2 virus-like particles (VLP)-based ELISA (M4ELISA) with previously reported results using a glutathione S-transferase (GST)-L1-based immunoassay (GST-L1-MIA) [49]. As expected, lower HPV antibody concentrations were found in FV urine than in serum. ...
... The findings of our investigation corroborate previous studies regarding the high prevalence of HPV infection broadly, and oncogenic HPV infection (i.e., hrHPV) specifically, in sexual minority men (SMM) and transgender women (Baldwin et al., 2003;Cranston et al., 2019;Glick et al., 2014;Mooij et al., 2013;Singh et al., 2019;van Aar et al., 2013;Wei et al., 2021). The relatively young age of our sample-cisgender SMM and transgender women (TW) who came of age after the FDA-approved HPV vaccination for adolescents assigned male at birth in 2009-is a call to action for more strategic development and implementation of gender-inclusive interventions to increase HPV vaccination uptake among young SMM and TW. ...
... It is believed that protection by the VLP vaccines against HPV infection and disease occurs via the induction of HPV typespecific neutralizing antibodies against the L1 capsid proteins on the VLP surface [5,6]. Similar antigenic sites on related papillomaviruses may elicit cross-reactive antibody responses [7] such as against HPV types in the Alpha-Papillomavirus species group, A7 (HPV18-related: 39, 45, 59, 68) and A9 (HPV16-related: 31,33,35,52,58) [8]. Typically, studies have been conducted on the cross-protective efficacy [9][10][11][12] and effectiveness [13] of the bivalent and quadrivalent HPV vaccines and have demonstrated inconsistent findings on cross-protective effect against non-vaccine HPV types covered by the nonavalent vaccine. ...
... To our knowledge, the only study that has examined this interval found that extended intervals resulted in similar levels of geometric mean IgG antibody titres when the second dose was given 6 months or 3-8 years after the first dose. 40 Finally, WHO recommended that countries consider routine vaccination of girls aged 9 years with a 3-5 year extended interval between doses (with a catch-up programme at age 14 years) after careful consideration of its programmatic challenges, and with a clear and well planned communication strategy. 10 Our study has five major strengths. ...
... 10 In the United States, HPV seroprevalence was assessed in the National Health and Nutrition Examination Survey (NHANES); in this national survey, among 169 MSM who identified as gay/bisexual during 2003-2010, seroprevalence of quadrivalent HPV vaccine types 6/11/16/18 was 42.6%, higher than among other men (13.2%). 11 For oral HPV infections, in a 2016 meta-analysis of data from five studies among HIV-negative MSM, pooled prevalence of high-risk HPV was 9.1% (95% CI: 4.0-14.2%). 12 For histological high-grade AIN among HIVnegative men, a meta-analysis of six studies reported that pooled prevalence was 21.5% (95% CI: 13.7%-29.3%), ...